Navigation Links
2012 Gastroinstestinal Cancers Symposium reveals new advances aimed at improving treatment, prognosis and detection of GI cancers
Date:1/17/2012

ALEXANDRIA, Va. New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.

Four important studies were highlighted today in a live presscast:

1)Biomarkers Promising for Detecting Barrett's Esophagus Patients at High Risk for Esophageal Cancer: Newly found biomarkers could eventually improve early detection of esophageal cancer in patients with Barrett's esophagus (BE), a condition that significantly increases esophageal cancer risk. Using a special microscope, researchers identified three optical biomarkers in cells of the esophagus lining, which enabled them to stratify patients' risks of progressing to cancer.

2) New Test Shows Promise for Detecting Early Stage Pancreatic Cancer: A new blood-based biomarker test correctly identified nearly two-thirds of patients with early stage pancreatic cancer, which has historically been extremely difficult to detect. When combined with another tumor marker commonly used to monitor disease progression, the new test found 85 percent of patients with pancreatic cancer.

3) Study Finds Prognostic Factors for Rare Neuroendocrine Tumors, Suggests Everolimus May Be More Beneficial Than Previously Shown: Researchers re-analyzing the results of a large phase III study of patients with advanced neuroendocrine tumors (NET) found certain factors predict which individuals are at greatest risk for neuroendocrine tumor progression and more likely to need active therapy. The re-analysis also showed that combining the drug everolimus (Afinitor) with another drug, octreotide, halted tumor growth for a longer period that previously shown, compared to octreotide alone.

4) Multi-Targeted Drug Improves Survival in Certain Patients with Metastatic Colorectal Cancer: An international phase III trial showed that single-agent treatment with the investigational drug regorafenib significantly improves survival and delays cancer progression in patients with metastatic colorectal cancer that has progressed despite other approved treatments, as compared to treatment with placebo and supportive care. Regorafenib is a novel, oral agent that targets multiple biological pathways involved in cancer development and growth.

"Research continues to focus on improving the lives of patients with gastrointestinal cancers in a number of ways, as we better understand how cancer develops and progresses, and develop new therapies and methods of early detection," said Morton Kahlenberg, MD, who moderated the presscast. "At this conference, we will see the results of new studies showing novel approaches to earlier detection and treatment in some of our deadliest and hardest to treat cancers."

Gastrointestinal cancers include those of the colon/rectum, stomach, pancreas, esophagus, small intestine, anus and other digestive organs. In 202, nearly 285,000 people in the U.S. will be diagnosed with these cancers and more than 142,000 will die from them.*


'/>"/>

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Gene links rare and unrelated cancers
2. Wistar receives $4.7 million to develop drug against Epstein-Barr virus-related cancers
3. Key genetic error found in family of blood cancers
4. A gene that protects against colorectal cancers
5. Heart drug may be effective for managing certain cancers: Queens University study
6. Two New Drug Combos May Fight Advanced Breast Cancers
7. Family Tree May Affect Diagnosis Age in Some Breast Cancers
8. British Screening Program Finding More Early Stage Colon Cancers
9. HIV Patients at Heightened Risk for Certain Cancers
10. BRAF addiction of thyroid cancers makes them therapeutically vulnerable
11. New drug combo targets multiple cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ ... during the summer of 2016. The program was made possible by a Pennsylvania ... Department of Health and Human Services Administration. The broadcast, Use Your Head: ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
Breaking Medicine Technology: